预约演示

Uniquity Bio launches with $300m and an MSD Phase II asset to boot

2024-05-16

交易

临床2期并购免疫疗法临床申请临床1期

Uniquity is eyeing pipeline growth alongside advancing solrikitug in COPD and asthma. Credit: Shutterstock/ peterschreiber.media.

Uniquityinvestment firm Blackstone Life Sciences has pusolrikitugthe COPDrs onasthmaatest pharma company to hit the immunology and inflammation arena.

Based in Pennsylvania, UBlackstone Life Sciencesched with $300m in capital from Blackstone.inflammation

Uniquity Bio’s most valuablUniquity Biorguably a monoclonal antibody in-licensedBlackstone solrikitug. The drug targets thymic stromal lymphopoietin (TSLP) and has recently been cleared for use in clinical trials by the US Food and Drug Administration (FDA).

Uniquity Biod it will launch Phase II trials in chronic obstructive pulmonary disease MSDPDsolrikitugma.thymic stromal lymphopoietin (TSLP)Food and Drug Administration (FDA)

Uniquityet size for COPD in the US was estimatedchronic obstructive pulmonary disease (COPD)of thasthmama market in the country was approximately $7.2bn in the same year, according to GlobalData’s Pharma Intelligence Centre.

See Also:DM-5167 by COPD Bio for Solid Tumor: Likelihood of Approvalasthma

BBI-825 bDM-5167lessDime Bio MetaSolid Tumorrectal Cancer: Likelihood of Approval

GlobalData is the parent company of Pharmaceutical Technology.

BBI-825he uBoundless Bios wilMetastatic Colorectal Cancers, Uniquity suggested the antibody could have applications in a wide range of immunology and inflammation programmes.

Uniquity CEO Brian Lortie said solrikitug “has the potential to be a life-changing medication for a significant number of patients who currently have very limited treatment options”, and that the company is “excited to move into the next phase of development.”

Uniquity gave no further details on Pharmaceutical Technologyng Phase II trials. But Blackstone Life Sciences’ global head Nicholas Galakatos reckons that the advancement of solrikitug will accompany an expanding pipeline for startups.

Galakatos said: “We are proud to partner with Uniquity’s teaUniquityeran industry leaders as they advance solrikitug and expand their immunology and iinflammationpipeline with additional programs in the near future.”

Uniquitygy and inflammation aresolrikituge hot areas to be a part of in the current pharma landscape. In February, inflammatory disease specialist Aiolos Bio was acquired by GSK in a $1.4bn deal. Aiolos had launched not long before in October 2023 with $200m and a monoclonal antibody that also targeted TSLP.

Uniquitythe space is Mirador Therapeutics which launched in late March 2024. Ushered Blackstone Life Sciences MSD-bought Prometheus, the company secured $400m in Series A finsolrikitug

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构

Uniquity Bio, Inc.